Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Total Debt (2018 - 2019)

Historic Total Debt for 10x Genomics (TXG) over the last 2 years, with Q4 2019 value amounting to $29.7 million.

  • 10x Genomics' Total Debt rose 14.49% to $29.7 million in Q4 2019 from the same period last year, while for Dec 2019 it was $29.7 million, marking a year-over-year increase of 14.49%. This contributed to the annual value of $29.7 million for FY2019, which is 14.49% up from last year.
  • 10x Genomics' Total Debt amounted to $29.7 million in Q4 2019, which was up 14.49% from $29.7 million recorded in Q3 2019.
  • Over the past 5 years, 10x Genomics' Total Debt peaked at $29.7 million during Q4 2019, and registered a low of $29.7 million during Q4 2018.